Successful Treatment of End-stage Renal Disease in a Patient With Chronic Myeloid Leukemia by Kidney Transplantation and Tyrosine Kinase Inhibitors: A Case Report

Kazunobu Shinoda; Shinya Morita; Satoshi Tamaki; Ryohei Takahashi; Sotaro Kitaoka; Hiroshi Asanuma; Tadashi Yoshida; Mikio Okayama; Hidenori Kasahara; Shinichiro Okamoto; Mototsugu Oya

doi:10.1016/j.transproceed.2019.10.035

Successful Treatment of End-stage Renal Disease in a Patient With Chronic Myeloid Leukemia by Kidney Transplantation and Tyrosine Kinase Inhibitors: A Case Report

Kazunobu Shinoda, Shinya Morita, Satoshi Tamaki, Ryohei Takahashi, Sotaro Kitaoka, Hiroshi Asanuma, Tadashi Yoshida, Mikio Okayama, Hidenori Kasahara, Shinichiro Okamoto, Mototsugu Oya

研究成果: Article › 査読

抄録

Consensus regarding kidney transplantation feasibility in patients with chronic myeloid leukemia (CML) well controlled by tyrosine kinase inhibitors has not yet been achieved. Here, we report a patient with CML well controlled by tyrosine kinase inhibitors who developed end-stage renal disease during treatment and underwent kidney transplantation. CML activity has been carefully and successfully controlled for 4 years post-transplant. Very cautious dose adjustment and temporary cessation of nilotinib were required because kidney function fluctuated in reference to the doses of nilotinib.

本文言語	English
ページ（範囲）	604-607
ページ数	4
ジャーナル	Transplantation Proceedings
巻	52
号	2
DOI	https://doi.org/10.1016/j.transproceed.2019.10.035
出版ステータス	Published - 2020 3月

ASJC Scopus subject areas

外科
移植

文献へのアクセス

10.1016/j.transproceed.2019.10.035

他のファイルとリンク

フィンガープリント

「Successful Treatment of End-stage Renal Disease in a Patient With Chronic Myeloid Leukemia by Kidney Transplantation and Tyrosine Kinase Inhibitors: A Case Report」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Shinoda, K., Morita, S., Tamaki, S., Takahashi, R., Kitaoka, S., Asanuma, H., Yoshida, T., Okayama, M., Kasahara, H., Okamoto, S., & Oya, M. (2020). Successful Treatment of End-stage Renal Disease in a Patient With Chronic Myeloid Leukemia by Kidney Transplantation and Tyrosine Kinase Inhibitors: A Case Report. Transplantation Proceedings, 52(2), 604-607. https://doi.org/10.1016/j.transproceed.2019.10.035

Shinoda, K, Morita, S, Tamaki, S, Takahashi, R, Kitaoka, S, Asanuma, H , Yoshida, T, Okayama, M, Kasahara, H, Okamoto, S & Oya, M 2020, 'Successful Treatment of End-stage Renal Disease in a Patient With Chronic Myeloid Leukemia by Kidney Transplantation and Tyrosine Kinase Inhibitors: A Case Report', Transplantation Proceedings, vol. 52, no. 2, pp. 604-607. https://doi.org/10.1016/j.transproceed.2019.10.035

@article{e2a3e7b920dc47a0bdad1ea00be02d00,

title = "Successful Treatment of End-stage Renal Disease in a Patient With Chronic Myeloid Leukemia by Kidney Transplantation and Tyrosine Kinase Inhibitors: A Case Report",

abstract = "Consensus regarding kidney transplantation feasibility in patients with chronic myeloid leukemia (CML) well controlled by tyrosine kinase inhibitors has not yet been achieved. Here, we report a patient with CML well controlled by tyrosine kinase inhibitors who developed end-stage renal disease during treatment and underwent kidney transplantation. CML activity has been carefully and successfully controlled for 4 years post-transplant. Very cautious dose adjustment and temporary cessation of nilotinib were required because kidney function fluctuated in reference to the doses of nilotinib.",

author = "Kazunobu Shinoda and Shinya Morita and Satoshi Tamaki and Ryohei Takahashi and Sotaro Kitaoka and Hiroshi Asanuma and Tadashi Yoshida and Mikio Okayama and Hidenori Kasahara and Shinichiro Okamoto and Mototsugu Oya",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = mar,

doi = "10.1016/j.transproceed.2019.10.035",

language = "English",

volume = "52",

pages = "604--607",

journal = "Transplantation Proceedings",

issn = "0041-1345",

publisher = "Elsevier USA",

number = "2",

}

TY - JOUR

T1 - Successful Treatment of End-stage Renal Disease in a Patient With Chronic Myeloid Leukemia by Kidney Transplantation and Tyrosine Kinase Inhibitors

T2 - A Case Report

AU - Shinoda, Kazunobu

AU - Morita, Shinya

AU - Tamaki, Satoshi

AU - Takahashi, Ryohei

AU - Kitaoka, Sotaro

AU - Asanuma, Hiroshi

AU - Yoshida, Tadashi

AU - Okayama, Mikio

AU - Kasahara, Hidenori

AU - Okamoto, Shinichiro

AU - Oya, Mototsugu

PY - 2020/3

Y1 - 2020/3

N2 - Consensus regarding kidney transplantation feasibility in patients with chronic myeloid leukemia (CML) well controlled by tyrosine kinase inhibitors has not yet been achieved. Here, we report a patient with CML well controlled by tyrosine kinase inhibitors who developed end-stage renal disease during treatment and underwent kidney transplantation. CML activity has been carefully and successfully controlled for 4 years post-transplant. Very cautious dose adjustment and temporary cessation of nilotinib were required because kidney function fluctuated in reference to the doses of nilotinib.

AB - Consensus regarding kidney transplantation feasibility in patients with chronic myeloid leukemia (CML) well controlled by tyrosine kinase inhibitors has not yet been achieved. Here, we report a patient with CML well controlled by tyrosine kinase inhibitors who developed end-stage renal disease during treatment and underwent kidney transplantation. CML activity has been carefully and successfully controlled for 4 years post-transplant. Very cautious dose adjustment and temporary cessation of nilotinib were required because kidney function fluctuated in reference to the doses of nilotinib.

UR - http://www.scopus.com/inward/record.url?scp=85078743743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078743743&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2019.10.035

DO - 10.1016/j.transproceed.2019.10.035

M3 - Article

C2 - 32029318

AN - SCOPUS:85078743743

SN - 0041-1345

VL - 52

SP - 604

EP - 607

JO - Transplantation Proceedings

JF - Transplantation Proceedings

IS - 2

ER -